Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtezoLACC
2024-515533-15-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Progression-free survival. Started Oct 2024; status: completed.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-515533-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515533-15-00.